6月24日复宏汉霖宣布公司自主研发的抗PD-1单抗汉斯状(斯鲁利单抗欧洲商品名:Hetronifly)已于近期相继获英国

智通财经
24 Jun
6月24日复宏汉霖宣布公司自主研发的抗PD-1单抗汉斯状(斯鲁利单抗欧洲商品名:Hetronifly)已于近期相继获英国药品和保健品监管局(MHRA)和印度中央药品标准控制组织(CDSCO)批准用于广泛期小细胞肺癌(ES-SCLC)的一线治疗由合作伙伴Intas及子公司Accord Healthcare负责该产品在当地的推广商品名为Hetronifly。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10